Abstract:Objective: Large cell neuroendocrine carcinomas of the lung display morphologic and immunohistochemical characteristics common to neuroendocrine tumors and the morphologic features of large cell carcinomas. Surgical resection of large cell neuroendocrine carcinomas in many series has been described, with 5-year actuarial survivals ranging from 13% to 57%. Considerable debate has emerged as to whether these tumors should be classified and treated as non-small cell lung cancers or small cell lung cancers. The objective of this study was to report the outcome of surgical resection in patients with large cell neuroendocrine carcinomas. Methods: An analysis of our tumor registry was performed to identify all patients undergoing surgical resection of lung cancer between July 1, 1988, and December 31, 2002, for large cell tumors. Cases were then segregated into large cell neuroendocrine carcinomas, mixed large cell neuroendocrine carcinomas (in which at least one portion of the tumor was a large cell neuroendocrine carcinoma), or large cell carcinomas on the basis of morphology and differentiation. Follow-up was complete on all patients, with a mean follow-up of 48 months. Type of resection, mortality, and survival by stage were analyzed. Kaplan-Meier survival was determined for all patients from the date of surgical intervention. Cox proportional hazards model analysis incorporating the variables of age, sex, histology, and stage estimated the effect of large cell neuroendocrine carcinomas and mixed large cell neuroendocrine carcinomas on recurrence and death. The stage of disease in all patients was assessed according to the 1997 American Joint Committee on Cancer guidelines. Results: Of the 2099 patients who underwent resection, 82 (3.9%) had large cell lung cancers. Perioperative mortality was 2.4%. Overall survival and freedom from recurrence at 5 years for the entire group was 47.1% and 58.4%, respectively. Overall survival by histologic subtype at 5 years was 30.2% for patients with large cell neuroendocrine carcinomas (n = 45), 30.3% for patients with mixed large cell neuroendocrine carcinomas (n = 11), and 71.3% for patients with large cell carcinomas (n = 21). Survival was significantly worse for patients with large cell neuroendocrine carcinomas than for patients with large cell carcinomas ( P = .013). The presence of large cell neuroendocrine carcinomas in the specimen (the large cell neuroendocrine carcinoma and mixed large cell neuroendocrine carcinoma groups combined) was significantly associated with decreased survival (relative risk, 2.44; 95% confidence interval 1.29-4.58; P = .003) and decreased freedom from recurrence (relative risk, 4.52; 95% confidence interval, 1.76-11.57; P < .001). Conclusion: Patients with large cell neuroendocrine carcinomas have a significantly worse survival after resection than patients with large cell carcinomas, even in stage I disease. Accurate differentiation of large cell neuroendocrine carcinoma from large cell carcinoma is important because it identifies those patients at highest risk for the development of recurrent lung cancer.

Large Cell Neuroendocrine Prostate Cancer: Large Is Not Small

Abstract 476: Defining Two Populations of Prostate Cancer Cells with Distinct Molecular, Biological, and Tumor-Propagating Properties

Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells

Large-cell neuroendocrine tumor of the prostate: a case report and review of the literature

Systemic metastases in large cell neuroendocrine prostate cancer: a rare case report and literature review

A systematic review of primary large cell neuroendocrine carcinoma of the prostate

Endocrine and paracrine characteristics of neuroendocrine prostate cancer

Understanding the molecular regulators of neuroendocrine prostate cancer

Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma

Large-cell Basaloid Adenocarcinoma of the Lung: A Clinicopathologic Study of 12 Cases of a Distinctive Form of Lung Cancer Often Mistaken for Large-cell Neuroendocrine Carcinoma

Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis

Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?

Small cell neuroendocrine prostate cancer with adenocarcinoma components—case report and literature review

Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer

Treatment-related Neuroendocrine Prostate Carcinoma—Diagnostic and Molecular Correlates

Diagnosis and management of neuroendocrine prostate cancer

Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer

The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1

Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance.

Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

Clinical Intricacies and Advances in Neuroendocrine Tumors: An Organ-Based Multidisciplinary Approach